About RegenxBio’s Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye

Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections of anti-vascular endothelial growth factor (anti-VEGF) drugs into the gel-like substance (the vitreous humor) that fills the eye between the lens and the retina. The currently used age-related wet macular degeneration injections are: Lucentis, which belongs to Genentech (a Roche (RHHBY) company) and EYLEA®, which belongs to Regeneron (REGN). 


RegenxBio (RGNX) is a gene therapy company that we picked for the Prohost Portfolio . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.